Page 12 - Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

CUAJ – Consensus Statement Warren et al
Unresectable locally advanced and metastatic urothelial carcinoma

References

1. Canadian Cancer Statistics Advisory Committee: Canadian Cancer Society. Canadian
Cancer Statistics 2018: Toronto, ON. www.cancer.ca/en. Accessed February 20, 2019.
2. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with
metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet
Oncol 2011;12:211-14.
3. Gonzalez CM, Jordan E, Zabor EC, et al. Split-dose cisplatin as an alternative to every-3-
week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer. J Clin
Oncol 2015;33:7S:373.
4. Morales-Barrera R, Bellmunt J, Suárez C, et al. Cisplatin and gemcitabine administered
every two weeks in patients with locally advanced or metastatic urothelial carcinoma and
impaired renal function. Eur J Cancer 2012;48:1816-21.
5. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a
randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-08.
6. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus
methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder
cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin
Oncol 2000;17:3068-77.
7. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-
cell carcinoma and Prognostic Predicting Outcome of Therapy. J Clin Oncol
1999;17:3173-81.
8. Sternberg CN, De Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase
III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC
in advanced urothelial tract tumours. Eur J Cancer 2006;42:50-54.
9. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III
study of two dose-dense regimens MVAC versus gemcitabine/ cisplatin in patients with
inoperable, metastatic or relapsed urothelial cancer: A Hellenic Cooperative Oncology
Group study (HE 16/03). Ann Oncol 2013;24:1011-17.
10. Plimack ER, Hoffman-Censits JH, Kutikov A, et al. Neoadjuvant dose-dense gemcitabine
and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final
results of a multicenter phase II study. J Clin Oncol 2014;32:15S:4513.
11. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing
paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally
advanced or metastatic urothelial cancer without prior systemic therapy: EORTC
intergroup study 30987. J Clin Oncol 2012;30:1107-13.
12. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and
carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann
Oncol 2012;23:406-10.
13. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing
gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with
advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study
30986. J Clin Oncol 2012;30:191-99.